

CDC73 Antibody (Center) Blocking Peptide Synthetic peptide

Catalog # BP9181c

Specification

CDC73 Antibody (Center) Blocking Peptide - Product Information

Primary Accession

<u>Q6P1J9</u>

CDC73 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 79577

Other Names Parafibromin, Cell division cycle protein 73 homolog, Hyperparathyroidism 2 protein, CDC73, C1orf28, HRPT2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP9181c was selected from the Center region of human CDC73. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CDC73 Antibody (Center) Blocking Peptide - Protein Information

Name CDC73

Synonyms C1orf28, HRPT2

Function

Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser- 5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcriptional activity of



KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors.

Cellular Location Nucleus

Tissue Location Found in adrenal and parathyroid glands, kidney and heart.

CDC73 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

CDC73 Antibody (Center) Blocking Peptide - Images

CDC73 Antibody (Center) Blocking Peptide - Background

CDC73 encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin.

CDC73 Antibody (Center) Blocking Peptide - References

Vierimaa,O., et.al., J. Endocrinol. Invest. 32 (6), 512-518 (2009)Hahn,M.A., et.al., J. Endocrinol. 201 (3), 387-396 (2009)